Bachem Holding AG (BANB.SW) Stock Analysis & Winston Score

Bachem Holding AG is a Swiss company that makes the chemical building blocks used to create peptide and oligonucleotide drugs. Peptides are small protein-like molecules that pharmaceutical and biotech companies use to treat diseases like diabetes, obesity, and cancer. Bachem is one of the largest contract manufacturers of these ingredients in the world, supplying drug makers rather than selling medicines directly to patients. Bachem earns money by manufacturing active pharmaceutical ingredients on contract for large drug companies and smaller biotech firms. It operates primarily from Switzerland, with additional facilities in the United States, United Kingdom, and Germany, and generates roughly $700–800 million in annual revenue. Its moat comes from highly specialized chemistry expertise, strict regulatory certifications, and long-term customer relationships that are difficult to replace quickly. The biggest growth driver is rising demand for GLP-1 peptide drugs used in obesity and diabetes treatment, though heavy reliance on a small number of large customers and significant capital spending on new capacity represent key risks.